The World Health Organization has “pre-qualified” a new Ebola vaccine in record time, just a day after the vaccine, Ervebo, received European regulatory approval. “This is the fastest vaccine prequalification process ever conducted by WHO,” said the organization in press release Tuesday evening. The WHO approval was described as a “critical step that will help […] Continue reading ->
A G20 Health Ministers Declaration, issued after a two-day meeting of ministers in Okayama Japan, has endorsed rapid achievement of universal health coverage, a more effective support of healthy ageing, increased attention to health emergencies and their underlying causes such as poverty and weak health systems, and more forceful action on antimicrobial resistance (AMR). The […] Continue reading ->
In August, the Democratic Republic of the Congo (DRC) passed a milestone—surpassing 3,000 cases of Ebola since the outbreak began over a year ago. While the number of new infections has since slowed, there continue to be cases in hard to reach areas, posing challenges to response teams. The outbreak response has been complex, with […] Continue reading ->
Trauma surgeon and veteran field worker, Christos Christou, has taken over the Médecins Sans Frontières (MSF) reins as International President, following his election by the organization’s International General Assembly last June. Christou, former president of the MSF Greece Board of Directors, will be faced with the leadership challenges of an organization that has grown from […] Continue reading ->
[US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading ->
[Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading ->